📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Endacea

1.1 - Company Overview

Endacea Logo

Endacea

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biopharmaceutical therapies targeting the A1 adenosine receptor, including L-97-1, an intravenous A1 adenosine receptor antagonist for sepsis and acute renal failure, and a mutant plasmid cDNA for cancer administered as an intratumor injection. Both programs are in the preclinical stage.

Products and services

  • Mutant plasmid cDNA: A preclinical-stage, intratumor-injection cancer treatment utilizing mutant plasmid cDNA for the A1 adenosine receptor, engineered for localized administration directly within tumors
  • L-97-1: An intravenous, preclinical-stage A1 adenosine receptor antagonist engineered to treat sepsis and acute renal failure through targeted A1 receptor inhibition

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Endacea

Omeros Logo

Omeros

HQ: United States Website
  • Description: Provider of clinical-stage biopharmaceutical therapies for inflammation and central nervous system disorders, including MASP-2 antibodies (narsoplimab, OMS1029) for lectin pathway diseases such as TA-TMA and lupus nephritis; MASP-3 antibody (OMS906) for PNH; small-molecule PDE7 (OMS527) and PPARγ (OMS405) candidates for addiction; and GPR174 inhibitors for cancer immunotherapy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Omeros company profile →
Herantis Pharma Logo

Herantis Pharma

HQ: Finland Website
  • Description: Provider of pharmaceutical therapies targeting unmet clinical needs, including HER-096, a small synthetic peptidomimetic based on the CDNF protein's active site for treating Parkinson’s disease, designed for subcutaneous administration and demonstrating good safety, tolerability, and efficient blood-brain barrier penetration in Phase 1a clinical trials.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Herantis Pharma company profile →
Mavu Pharma Logo

Mavu Pharma

HQ: United States Website
  • Description: Provider of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mavu Pharma company profile →
Prismic Pharmaceuticals Logo

Prismic Pharmaceuticals

HQ: United States Website
  • Description: Provider of novel prescription medical drugs for inflammatory diseases and prescription medical foods for the clinical dietary management of metabolic processes associated with disorders common in the aging 'baby boomer' population, including central nervous system disorders.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Prismic Pharmaceuticals company profile →
NeRRe Therapeutics Logo

NeRRe Therapeutics

HQ: United Kingdom Website
  • Description: Provider of biotechnology R&D focused on clinical and pre-clinical neurokinin receptor antagonists, including Orvepitant, a neurokinin-1 receptor antagonist in development for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF). Founded in 2012 and based in Stevenage, United Kingdom.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NeRRe Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Endacea

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Endacea

2.2 - Growth funds investing in similar companies to Endacea

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Endacea

4.2 - Public trading comparable groups for Endacea

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Endacea

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Endacea

What does Endacea do?

Endacea is a provider of biopharmaceutical therapies targeting the A1 adenosine receptor, including L-97-1, an intravenous A1 adenosine receptor antagonist for sepsis and acute renal failure, and a mutant plasmid cDNA for cancer administered as an intratumor injection. Both programs are in the preclinical stage.

Who are Endacea's competitors?

Endacea's competitors and similar companies include Omeros, Herantis Pharma, Mavu Pharma, Prismic Pharmaceuticals, and NeRRe Therapeutics.

Where is Endacea headquartered?

Endacea is headquartered in United States.

How many employees does Endacea have?

Endacea has 1,000 employees 🔒.

When was Endacea founded?

Endacea was founded in 2010 🔒.

What sector and industry vertical is Endacea in?

Endacea is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Endacea

Who are the top strategic acquirers in Endacea's sector and industry

Top strategic M&A buyers and acquirers in Endacea's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Endacea?

Top strategic M&A buyers groups and sectors for Endacea include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Endacea's sector and industry vertical

Which are the top PE firms investing in Endacea's sector and industry vertical?

Top PE firms investing in Endacea's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Endacea's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Endacea's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Endacea's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Endacea include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Endacea's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Endacea?

The key public trading comparables and valuation benchmarks for Endacea include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Endacea for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Endacea with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Endacea's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Endacea with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Endacea's' sector and industry vertical?

Access recent funding rounds and capital raises in Endacea's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Endacea